pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

917 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT792Endpoints594BioPharma Dive228onclive165BioSpace66Fierce Biotech64raps29
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology
  • Biotech pay analysis: 12 execs with $35M+ M&A golden parachutes
    A dozen biotech executives took home nearly $1 billion worth of exit packages from selling their companies, an Endpoints News analysis found. The drug industry is undergoing a historic stretch of…
    Endpoints · 1mo ago↗ source
  • AstraZeneca’s ‘extensive’ obesity drug push; $125M for ultrasound-aided genetic medicine
    <figure><div><img src="https://imgproxy.divecdn.com/idsdMAHsPbXObDUtQW2qRG7uveBUVv6HCTn9NTtlDOI/g:nowe:0:0/c:1207:682/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0x…
    BioPharma Dive · 1mo ago↗ source
  • Ethyreal lands $101M to treat both Graves' and thyroid eye disease
    A biotech backed by Atlas Venture and Medicxi uncloaked on Wednesday morning to tackle the related autoimmune conditions Graves' disease and thyroid eye disease, and the startup plans to enter the…
← prev
page 20 of 37
next →
6
Hematology6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
Endpoints · 1mo ago
↗ source
  • Sanofi to mull riliprubart’s future after stopping late-stage nerve disease study
    Sanofi is ending a Phase 3 trial of its antibody drug in a rare neurological disorder after an independent committee said the study was unlikely to show sufficient efficacy. The broader future of…
    Endpoints · 1mo ago↗ source
  • Parabilis' $670M IPO sets new biotech record, will fund cancer drug
    Despite all the noise around massive upcoming IPOs for AI giants, a drug developer was able to attract enough investor interest to achieve the biggest Nasdaq debut the biopharma industry has ever s…
    Endpoints · 1mo ago↗ source
  • Eli Lilly's claims data deadline may kick off new 340B fight
    Eli Lilly’s deadline has passed for hospitals to comply with its new 340B claims data policy, and for now the pharma company is staying mum on its next steps. But just because Lilly is declining ...
    Endpoints · 1mo ago↗ source
  • Grace Science says FDA bottleneck jeopardizes rare disease therapy
    Grace Science appeared to be one of the few companies fighting ultra-rare diseases whose gene therapy candidate might make it across the finish line. Co-founded by Nobel laureate Carolyn Bertozzi…
    Endpoints · 1mo ago↗ source
  • Merck, Gilead report mixed outcomes in key lung cancer, HIV studies
    <figure><div><img src="https://imgproxy.divecdn.com/lM3CYabLlmazQYt-COfrxYzxdsO20VnU3PS1vfCq2lE/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xMjEwOTMxMjkxXzEua…
    BioPharma Dive · 1mo ago↗ source
  • A different approach to lowering healthcare costs
    Last month, Garner Health raised $100 million, vaulting its valuation to $2.7 billion. At first, this startup sounded more like a doctor-rankings company, which I’d typically think of as more ...
    Endpoints · 1mo ago↗ source
  • Stealthy startup Treeline plans a reverse merger
    <figure><div><img src="https://imgproxy.divecdn.com/zFaUfmdVIipdm_YpQNEDluIv-xqM-1mOqftBuOls6_g/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9UcmVlTGluZV8xMDAuanBn.webp"/></div…
    BioPharma Dive · 1mo ago↗ source
  • How K Health moved AI chatbots into hospitals
    Startups that fashion themselves as AI doctors that patients can chat with have gained traction over the last year. One of these startups, K Health, began in 2016 as a symptom checker ...
    Endpoints · 1mo ago↗ source
  • Lilly offers up to $1B for Alzheimer's drug; Bial cuts failed Parkinson's drug
    Plus news about Parabilis Medicines, RA Capital, Tango Therapeutics, Ideaya Biosciences, Bavarian Nordic and Cartesian Therapeutics 💸 Lilly’s $1B Alzheimer’s deal: The Indianapolis drugmaker wil…
    Endpoints · 1mo ago↗ source
  • Trodelvy misses in lung cancer, but Gilead and Merck have an HIV success
    Gilead Sciences and Merck have reported a hit and a miss for their Phase 3 HIV and lung cancer programs, respectively, but investors were largely braced for impact, according to Wall Street. The…
    Endpoints · 1mo ago↗ source
  • Endpoints Women in Biopharma: Nominate for 2026
    Today we’re opening nominations for our eighth annual Women in Biopharma special project. Women in Biopharma is one of my favorite traditions at Endpoints. Each year, we take a hard look at the s…
    Endpoints · 1mo ago↗ source
  • Pharma and biotech salaries: Top-paying companies of 2025
    The typical worker in biopharma made $116,648 in 2025, according to an Endpoints News pay analysis, earning about 30% more than the typical employee of an S&P 500 company. The latest Endpoint…
    Endpoints · 1mo ago↗ source
  • GSK boosts cancer pipeline with $11B Nuvalent buyout
    <figure><div><img src="https://imgproxy.divecdn.com/mDk-h3NLB8udDPFuDlI7IPou1i9tJKJYucQXUnhK9vA/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0yMTc3MzEzMjc4LmpwZ…
    BioPharma Dive · 1mo ago↗ source
  • Post-Hoc Live: How much is everyone in biopharma getting paid?
    The one law of CEO pay packages: They keep getting bigger. Yesterday, we published the first installment of Endpoints News’ annual biopharma compensation project. Following our analysis of the in…
    Endpoints · 1mo ago↗ source
  • WuXi AppTec added to Pentagon's list of companies linked to Chinese military
    Another wave of scrutiny has hit WuXi AppTec through its re-inclusion in the Pentagon’s updated list of companies that have ties to the Chinese military. With its appearance on the list ...
    Endpoints · 1mo ago↗ source
  • GSK to acquire Nuvalent and its two cancer drugs under FDA review for $10.6B
    GSK is making one of the largest biotech acquisitions in its history to gain access to two experimental lung cancer medicines that are due for FDA approval decisions later this year. The UK drugm…
    Endpoints · 1mo ago↗ source
  • #ADA26: AstraZeneca's GLP-1 pill cuts weight by 10.5% after six months
    The race to be third to market with an obesity pill has a number of contenders, including Roche, Pfizer and Structure Therapeutics. On Monday, AstraZeneca set out its own stall with data on a pill ...
    Endpoints · 1mo ago↗ source
  • City banks nearly $100M for next-gen RNAi drugs
    <figure><div><img src="https://imgproxy.divecdn.com/pxC2yW1qZhMv8FFHGtViPA2KryY3_Pfu7kxPvvCensY/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xMjk3MDM0MzI5LmpwZ…
    BioPharma Dive · 1mo ago↗ source
  • Incyte CEO sees $2B Vega deal aiding a post-Jakafi future
    Bill Meury has been in or led the C-suite of several biopharma companies that have constructed multibillion-dollar exits over the past decade: Allergan, Karuna and Anthos. Now, he’s the one buyin…
    Endpoints · 1mo ago↗ source
  • City Therapeutics gets $99M to gather data on three RNAi medicines
    City Therapeutics, the next-gen RNAi startup founded and led by former Alnylam executives, has collected $99.5 million to fund the clinical development of its first three candidates and expand into…
    Endpoints · 1mo ago↗ source
  • Roche stakes $700M on Nurix’s protein-degrading drug
    <p>Potentially worth up to $2.3 billion, the collaboration is a bet that drugs able to eliminate the “BTK” enzyme will prove superior to existing medicines that block its activity.</p>
    BioPharma Dive · 1mo ago↗ source
  • GoHealth files for bankruptcy, as Medicare Advantage insurers pull back
    The volatile Medicare Advantage market can now count GoHealth as a casualty. GoHealth, a health insurance marketplace focused on seniors, on Sunday voluntarily filed for Chapter 11 bankruptcy in…
    Endpoints · 1mo ago↗ source